Logo image
Back
A 3-year landmark overall survival analysis of RP1 plus nivolumab in patients with anti-PD-1-failed melanoma from the IGNYTE clinical trial
Abstract   Peer reviewed

A 3-year landmark overall survival analysis of RP1 plus nivolumab in patients with anti-PD-1-failed melanoma from the IGNYTE clinical trial

Michael K.K. Wong, Joseph J. Sacco, Gino Kim In, Eva Muñoz Couselo, Dirk Schadendorf, Jiaxin Niu, Georgia Beasley, Trisha Michel Wise-Draper, Bartosz Chmielowski, Judith Michels, …
Journal of clinical oncology, Vol.44(16_suppl), pp.9518-9518
06/01/2026
DOI: 10.1200/JCO.2026.44.16_suppl.9518

View Online

Abstract

9518Background: Advanced melanoma has a high mortality rate; however, survival for patients (pts) treated with anti-PD-1-based therapy tends to plateau at 3-4 years, suggesting that pts alive at 3 years are likely to have prolonged benefit. This highlights the need for novel therapies that offer increased survival beyond 3-4 years. RP1 (vusolimogene oderparepvec) is an HSV-1-based oncolytic immunotherapy expressing GM-CSF and a fusogenic glycoprotein (GALV-GP-R−). In the IGNYTE trial (data cutoff [DCO]: 15OCT2024), pts with advanced melanoma that had confirmed progression on anti-PD-1 therapy who received RP1 + nivolumab (nivo) had an objective response rate by RECIST 1.1 of 33.6% (16.4% complete response); median duration of response was 24.8 months. Here, we present a 3-year survival analysis of pts treated with RP1 + nivo from IGNYTE (last pt in: 9MAR2023; DCO: 11JUN2025). Methods: Pts ≥18 years with advanced melanoma and confirmed progression while being treated for ≥8 weeks with anti-PD-1 ± anti-CTLA-4 as the last prior therapy were enrolled (NCT03767348). An initial dose of RP1 was administered intratumorally (1 × 106 PFU/mL), followed by up to 7 doses every 2 weeks (Q2W; 1 × 107 PFU/mL) in combination with intravenous nivo 240 mg Q2W/480 mg Q4W for up to 2 years; additional RP1 was allowed if protocol-specified criteria were met. This updated analysis evaluated overall survival (OS) using the Kaplan-Meier (KM) method. Results: Of 140 enrolled pts, 49.3% had stage IVM1b-d disease, 55.7% had PD-L1-negative tumors, 46.4% had prior anti-PD-1 + anti-CTLA-4 therapy, and 65.0% had primary resistance to prior anti-PD-1 (ie, progression within 6 months of starting the immediate prior course of anti-PD-1). The median (95% CI) OS was 32.2 (25.8, 39.2) months (the median OS follow-up was 3 years by reverse KM method). OS rates (95% CI) at 1, 2, and 3 years were 75.3% (66.9%, 81.9%), 61.6% (52.5%, 69.4%), and 45.5% (35.8%, 54.7%), respectively. Importantly, among responders (n=47), the 3-year OS rate (95% CI) was 81.8% (65.2%, 91.0%) vs 22.5% (12.6%, 34.2%) for non-responders (n=93). The 3-year OS rates were 41.8% in pts with stage IVM1b-d disease (n=69), 37.2% for those with PD-L1-negative tumors (n=78), 37.4% in pts with prior anti-PD-1 + anti-CTLA-4 therapy (n=65), and 44.8% in pts with primary resistance to anti-PD-1 (n=91). The safety profile for RP1 + nivo remained consistent with prior reports; no new safety signals were seen. Conclusions: The 3-year landmark OS rate of 45.5% in the overall population and 81.8% among responders provides further evidence that the deep and durable responses provided by RP1 + nivo translate into long term clinical benefit, including extended OS in pts with melanoma post-confirmed progression on prior anti-PD-1-based therapy. Clinical trial information: NCT03767348.
 613-135-2370-7650-2700 281-318-9082 613-135-244-3829-325 9 3 2 14 6 38092-21082 1

Details

Metrics

1 Record Views
Logo image